Antioxidant Role of the Lutein in Preterm Newborn — Early Administration of the Lutein/Zeaxanthin in Premature Newborns
Citation(s)
Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophth
Alberti A, Bolognini L, Macciantelli D, et al The radical cation of N,N-dimethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000; 26:253-267
Benzie IF, Strain JJ The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996 Jul 15;239(1):70-6.
Bonn D Keeping the stork at bay until the time is right. Lancet. 1998 Feb 21;351(9102):576.
Cohen, J (1969). Statistical power analysis for the behavioural sciences. New York: Academic Press
During A, Dawson HD, Harrison EH Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr. 2005 Oct;135(10):2305-12.
Fanaris, Bel BO, Guidettic E et al Ruolo della Luteina nella prevenzione delle patologie oculari nel neonato. Rivista Italiana di Medicina Pediatrica 2006;numero speciale:51-53
Faul F, Erdfelder E, Lang AG, Buchner A G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91.
Krinsky NI, Landrum JT, Bone RA Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003;23:171-201. Epub 2003 Feb 27. Review.
Krinsky NI Possible biologic mechanisms for a protective role of xanthophylls. J Nutr. 2002 Mar;132(3):540S-542S. Review.
Rajendran V, Pu YS, Chen BH An improved HPLC method for determination of carotenoids in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):99-106.
Santosa S, Jones PJ Oxidative stress in ocular disease: does lutein play a protective role? CMAJ. 2005 Oct 11;173(8):861-2.
Schweigert FJ, Bathe K, Chen F, Büscher U, Dudenhausen JW Effect of the stage of lactation in humans on carotenoid levels in milk, blood plasma and plasma lipoprotein fractions. Eur J Nutr. 2004 Feb;43(1):39-44. Epub 2004 Jan 6.
Shao A, Hathcock JN Risk assessment for the carotenoids lutein and lycopene. Regul Toxicol Pharmacol. 2006 Aug;45(3):289-98. Epub 2006 Jun 30. Review.
Shoji H, Koletzko B Oxidative stress and antioxidant protection in the perinatal period. Curr Opin Clin Nutr Metab Care. 2007 May;10(3):324-8. Review.
Sommerburg O, Keunen JE, Bird AC, van Kuijk FJ Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol. 1998 Aug;82(8):907-10.
Yanoff M and Duker i S (2005) "Ophthalmology" Edizione italiana ed 2003 ristampa 2005, Antonio Delfino Editore medicina-scienze, volume 1, cap 1.3
Yeum KJ, Ferland G, Patry J, Russell RM Relationship of plasma carotenoids, retinol and tocopherols in mothers and newborn infants. J Am Coll Nutr. 1998 Oct;17(5):442-7.
Evaluation of the Antioxidant Activity of Lutein/Zeaxanthin Early Administered to Premature Newborns
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.